Chimeric papillomavirus-like particles

Virology

Volumn 234, Issue 1, 1997, Pages 93-111

  Müller, Martin ^a   Zhou, Jian ^e   Reed, Tracey D ^a   Rittmüller, Claudia ^a   Burger, Alexander ^b   Gabelsberger, Josef ^c   Braspenning, Joris ^d   Gissmann, Lutz ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b MediGene AG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; VIRUS PROTEIN;

ARTICLE; BACULOVIRUS; CHIMERA; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; NONHUMAN; PRIORITY JOURNAL; VIRUS PARTICLE; VIRUS RECOMBINANT; WART VIRUS;

BOVINE PARVOVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; MAMMALIA; MIRIDAE; PAPILLOMAVIRUS; UNIDENTIFIED BACULOVIRUS;

EID: 0031582649     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.1997.8591     Document Type: Article

References (60)

1. Altmann A., Gissmann L., Jochmus I. Towards HPV vaccination. Viruses and Cancer. 1994;Cambridge Univ. Press, Cambridge. p. 71-80.
2. Baker T. S., Newcomb W. W., Olson N. H., Cowsert L. M., Olson C., Brown J. Structures of bovine and human papillomaviruses analysis by cryoelectron microscopy and three-dimensional image reconstruction. J. Biophys. 60:1991;1445-1456.
3. Benton C., Shahidullah H., Hunter J. A. A. Human Papillomaviruses in the immunosuppressed. Papillomavirus Rep. 3:1992;23-26.
4. Breitburd F., Kirnbauer R., Hubbert N. L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., Schiller J. T., Lowy D. R. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:1995;3959-3963.
5. Campo M. S. Vaccination against papillomavirus in cattle. Curr. Top. Microbiol Immunol. 186:1994;255-266.
6. Chen L. P., Thomas E. K., Hu S. L., Hellstrom I., Hellstrom K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA. 88:1991;110-114.
7. Christensen N. D., Kreider J. W., Shah K. V., Rando R. F. Detection of human serum antibodies that neutralize infectious human papillomavirus type 11 virions. J. Gen. Virol. 73:1992;1261-1267.
8. Christensen N. D., Kirnbauer R., Schiller J. T., Ghim S. J., Schlegel R., Jenson A. B., Kreider J. W. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 205:1994;329-335.
9. Christensen N. D., Reed C. A., Cladel N. M., Hall K., Leiserowitz G. S. Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific eptitopes on HPV-6. Virology. 224:1996a;477-486.
10. Christensen N. D., Reed C. A., Cladel N. M., Han R., Kreider J. W. Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J. Virol. 70:1996b;960-965.
11. Crawford L. V., Crawford E. M. A comparative study of polyoma and papillomaviruses. Virology. 21:1963;258-263.
12. Crum C. P., Ikenberg H., Richard R. M., Gissman L. Human papillomavirus type 16 and early cervical neoplasia. N. Engl. J. Med. 310:1984;880-883.
13. Favre M., Breitburg F., Croissant O., Orth G. Structural polypeptides of rabbit, bovine and human papillomaviruses. J. Virol. 15:1975;1239-1247.
14. Feltkamp M. C., Smits H. L., Vierboom M. P., Minnaar R. P., de-Jongh B. M., Drijfhout J. W., ter-Schegget J., Melief C. J., Kast W. M. Vaccination with cytotoxic T-lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:1993;2242-2249.
15. Galloway D. A., McDougall J. K. Human papillomaviruses and carcinomas. Adv. Virus. Res. 37:1989;125-171.
16. Gaukroger J. M., Chandrachud L. M., O'Neil B. W., Grindlay G. J., Knowles G., Campo M. S. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J. Gen. Virol. 77:1996;1577-1583.
17. Gissmann L. Human papillomaviruses and genital cancer. Semin. Cancer. Biol. 3:1992;253-261.
18. Greenfield I., Nickerson J., Penman S., Stanley M. Human papillomavirus 16 E7 protein is associated with the nuclear matrix. Proc. Natl. Acad. Sci. USA. 88:1991;11217-11221.
19. Hagensee M. E., Yaegashi N., Galloway D. A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol. 67:1993;315-322.
20. Heino P., Dillner J., Schwartz S. Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology. 214:1995;349-359.
21. Ho S. N., Hunt H. D., Horton R. M., Pullen J. K., Pease L. R. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:1989;51-59.
22. H. Ikenberg, 1991, Human papillomavirus DNA in invasive genital carcinomas, Genital Papillomavirus Infections, G. GrossS. JablonskaH. PfisterH. E. Stegner, 87, 112, Springer Verlag, Berlin.
23. Jha P. K., Beral V., Peto J., Hack S., Hermon C., Deacon J., Mant D., Chilvers C., Vessey M. P., Pike M. C., Müller M., Gissmann L. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet. 341:1993;1116-1118.
24. Jochmus-Kudielka I., Schneider A., Braun R., Kimmig R., Koldovsky U., Schneweis K. E., Seedorf K., Gissmann L. Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer. J. Natl. Cancer Inst. 81:1989;1698-1704.
25. Kennedy I. M., Haddow J. K., Clements J. B. Analysis of human papillomavirus type 16 late mRNA 3′ processing signals in vitro and in vivo. J. Virol. 64:1990;1825-1829.
26. Kennedy I. M., Haddow J. K., Clements J. B. A negative regulatory element in the human papillomavirus type 16 genome acts at the level of late mRNA stability. J. Virol. 65/4:1991;2093-2097.
27. Kirnbauer R., Booy F., Cheng N., Lowy D. R., Schiller J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl. Acad. Sci. USA. 89:1992;12180-12184.
28. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., Lowy D. R., Schiller J. T. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J. Virol. 67:1994;6929-6936.
29. McLean C. S., Churcher M. J., Meinke J., Smith G. L., Higgins G., Stanley M., Minson A. C. Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus. J. Clin. Pathol. 43:1990;488-492.
30. Meneguzzi G., Cerni C., Kieny M. P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181/1:1991;62-69.
31. Müller M., Viscidi R. P., Sun Y., Guerrero E., Hill P. M., Shah F., Bosch F. X., Munoz N., Gissmann L., Shah K. V. Antibodies to HPV-16 E6 and E7 proteins as markers for HPV-16- associated invasive cervical cancer. Virology. 187:1992;508-514.
32. Müller M., Gissmann L., Cristiano R. J., Sun X. Y., Frazer I. H., Jenson A. B., Alonso A., Zentgraf H., Zhou J. Papillomavirus capsid binding and uptake by cells from different tissues and species. J. Virol. 69:1995;948-954.
33. Paintsil J., Müller M., Picken M., Gissmann L., Zhou J. Carboxyl terminus of bovine papillomavirus type-1 L1 protein is not required for capsid formation. Virology. 223:1996;238-244.
34. Pisani P., Parkin D. M., Ferlay J. Estimates of the worldwide mortality from 18 major cancers in 1985 - Implications for prevention and projections of future burden. Int. J. Cancer. 55:1993;891-903.
35. Prober J. M., Trainor G. L., Dam R. J., Hobbs F. W., Robertson C. W., Zagursky R. J., Cocuzza A. J., Jensen M. A., Baumeister K. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science. 238:1987;336-341.
36. Ressing M. E., Sette A., Brandt R. M., Ruppert J., Wentworth P. A., Hartman M., Oseroff C., Grey H. M., Melief C. J., Kast W. M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:1995;5934-5943.
37. Roden R. B., Kirnbauer R., Jenson A. B., Lowy D. R., Schiller J. T. Interaction of papillomaviruses with the cell surface. J. Virol. 68:1994a;7260-7266.
38. Roden R. B., Weissinger E. M., Henderson D. W., Booy F., Kirnbauer R., Mushinski J. F., Lowy D. R., Schiller J. T. Neutralization of bovine papillomavirus by antibodies to L1 and L2 capsid proteins. J. Virol. 68:1994b;7570-7574.
39. Roden R. B., Hubbert N. L., Kirnbauer R., Breitburd F., Lowy D. R., Schiller J. T. Papillomavirus L1 capsids agglutinate mouse erythrocytes through a proteinaceous receptor. J. Virol. 69:1995;5147-5151.
40. Roden R. B., Greenstone H. L., Kirnbauer R., Booy F. P., Jessie J., Lowy D. R., Schiller J. T. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J. Virol. 70:1996a;5875-5883.
41. Roden R. B., Hubbert N. L., Kirnbauer R., Christensen N. D., Lowy D. R., Schiller J. T. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J. Virol. 70:1996b;3298-3301.
42. Rose R. C., Bonnez W., Reichman R. C., Garcea R. L. Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of virus-like particles. J. Virol. 67:1993;1936-1944.
43. Sasagawa T., Pushko P., Steers G., Gschmeissner S. E., Hajibagheri M. A., Finch J., Crawford L., Tommasino M. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology. 206:1995;126-135.
44. Schiller J. T., Roden R. B. S. Papillomavirus-like particles. Papillomavirus Rep. 6:1995;121-128.
45. Schirmbeck R., Bohm E., Reimann J. Virus-like particles induce MHC class I-restricted T cell responses. Intervirology. 39:1996;111-119.
46. Schwarz E., Freese U. K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314/6006:1985;111-114.
47. Smith L. H., Foster C., Hitchcock M. E., Leiserowitz G. S., Hall K., Isseroff R., Christensen N. D., Kreider J. W. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J. Invest. Dermatol. 105:1995;438-444.
48. Stöppler H., Stöppler M. C., Schlegel R. Transforming proteins of the papillomaviruses. Intervirol. 37:1994;168-179.
49. Suzich J. A., Ghim S. J., Palmer-Hill F. J., White W. I., Tamura J. K., Bell J. A., Newsome J. A., Jenson A. B., Schlegel R. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA. 92:1995;11553-11557.
50. Tan W., Felber B. K., Zolotukhin A. S., Pavlakis G. N., Schwartz S. Efficient expression of the human papillomavirus type 16 L1 protein in epithelial cells by using Rev and the Rev-responsive element of human immunodeficiency virus or the cis-acting transactivation element of simian retrovirus type 1. J. Virol. 69:1995;5607-5620.
51. Tindle R. W., Frazer I. H. Immune response to human papillomaviruses and the prospects for human papillomavirus-specific immunization. Curr. Top. Microbiol Immunol. 186:1994;217-253.
52. Viscidi R. P., Sun Y., Tsuzaki B., Bosch F. X., Munoz N., Shah K. V. Serological response in human papillomavirus-associated invasive cervical cancer. Int. J. Cancer. 55:1993;780-784.
53. Volpers C., Unckell F., Schirmacher P., Streeck R. E., Sapp M. Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J. Virol. 69:1995;3258-3264.
54. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in c4-1 cervical carcinoma cells. Cancer Res. 48:1988;3780-3786.
55. F. O. Wettstein, 1990, State of viral DNA and gene expression in benign vs. malignant tumors, Papillomaviruses and Human Cancer, H. Pfister, 155, 179, Boca Raton.
56. Zhou J., Doorbar J., Sun X. Y., Crawford L. V., McLean C. S., Frazer I. H. Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. Virology. 185:1991a;625-632.
57. Zhou J., Sun X. Y., Stenzel D. J., Frazer I. H. Expression of vaccinia recombinant hpv 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 185:1991b;251-257.
58. Zhou J., Stenzel D. J., Sun X. Y., Frazer I. H., Frazer I. Synthesis and assembly of infectious bovine papillomavirus particles in vitro. J. Gen. Virol. 74:1993;763-768.
59. Zhou J., Gissmann L., Zentgraf H., Müller H., Picken M., Müller M. Early phase in the infection of cultured cells with papillomavirus virions. Virology. 214:1995;167-176.
60. zur Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res. 49:1989;4677-4681.